Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

X
Trial Profile

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crisaborole (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CrisADe CORE 1
  • Sponsors Anacor Pharmaceuticals; Pfizer
  • Most Recent Events

    • 01 Jan 2024 Results of post hoc pooled analysis from NCT02118766 and NCT02118792, assess the efficacy and safety of crisaborole in patients with AD who had received prior treatment with (a) corticosteroids (systemic or topical) or topical calcineurin inhibitors (TCIs) or (b) topical corticosteroids (TCSs) or TCIs or (c) who were treatment-naive , published in the Dermatitis
    • 22 Feb 2023 Results of an analysis impact of crisaborole on sleep outcomes in pediatric patients atopic dermatitis from three clinical studies: CORE-1, CORE-2 and CrisADe CARE 1 study published in the Dermatology and Therapy
    • 16 Mar 2022 Results of post-hoc pooled analysis of two studies (AD-301: NCT02118766; AD-302: NCT02118792) assessing efficacy and safety of crisaborole ointment for the treatment of mild-to-moderate atopic dermatitis in pediatric patients, published in the Pediatric Drugs.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top